Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q4 2013

GCVRZ Guru Trades in Q4 2013

Jean-Marie Eveillard 229,402 sh (+16262.5%)
Michael Price 5,300,000 sh (+31.68%)
Mario Gabelli 972,820 sh (+4.47%)
Murray Stahl 15,940 sh (unchged)
David Abrams 11,658,873 sh (-62.61%)
» More
Q1 2014

GCVRZ Guru Trades in Q1 2014

Jean-Marie Eveillard 229,402 sh (unchged)
Murray Stahl 15,940 sh (unchged)
Michael Price 5,275,000 sh (-0.47%)
Mario Gabelli 631,351 sh (-35.1%)
» More
Q2 2014

GCVRZ Guru Trades in Q2 2014

Michael Price 5,275,000 sh (unchged)
Murray Stahl 15,940 sh (unchged)
Jean-Marie Eveillard 226,402 sh (-1.31%)
Mario Gabelli 560,351 sh (-11.25%)
» More
Q3 2014

GCVRZ Guru Trades in Q3 2014

Murray Stahl 15,940 sh (unchged)
Jean-Marie Eveillard 226,402 sh (unchged)
Mario Gabelli 303,351 sh (-45.86%)
Michael Price 1,275,000 sh (-75.83%)
» More
» Details

Insider Trades

Latest Guru Trades with GCVRZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2014-09-30 Reduce -75.83%0.24%$0.45 - $0.51 $ 0.7757%1275000
Mario Gabelli 2014-09-30 Reduce -45.86%$0.45 - $0.51 $ 0.7757%303351
Mario Gabelli 2014-03-31 Reduce -35.1%$0.3 - $0.47 $ 0.77108%631351
David Abrams 2013-12-31 Reduce -62.61%3.07%$0.32 - $2.04 $ 0.77-36%11658873
Michael Price 2013-12-31 Add 31.68%0.06%$0.32 - $2.04 $ 0.77-36%5300000
Jean-Marie Eveillard 2013-12-31 Add 16262.5%$0.32 - $2.04 $ 0.77-36%229402
Whitney Tilson 2013-09-30 Add 62.2%0.1%$1.82 - $2.04 $ 0.77-60%81100
Mario Gabelli 2012-12-31 Reduce -26.21%0.01%$1.67 - $1.89 $ 0.77-56%1188148
Michael Price 2012-03-31 Add 29.41%0.19%$1.25 - $1.37 $ 0.77-37%4400000
Jean-Marie Eveillard 2011-12-31 Reduce -99.53%$0.89 - $1.34 $ 0.77-31%1402
Michael Price 2011-09-30 Add 70%0.26%$0.99 - $2.56 $ 0.77-45%3400000
Jean-Marie Eveillard 2011-09-30 Reduce -81.3%0.01%$0.99 - $2.56 $ 0.77-45%301402
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT 37.00
GCVRZ's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GCVRZ: 37.00 )
GCVRZ' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 37

PEG 1.20
GCVRZ's PEG is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. GCVRZ: 1.20 )
GCVRZ' s 10-Year PEG Range
Min: 0   Max: 1.4
Current: 1.2

0
1.4

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare:KH, CTFO, GBG, URGP, GPRM » details
» More Articles for GCVRZ

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
France's Sanofi to start production in Saudi Dec 11 2014
GSK cuts U.S. sales and research jobs as market gets tougher Dec 03 2014
GSK to axe U.S. jobs as part of $1.6 bln cost cuts -sources Nov 30 2014
Market overview: Brent drops after OPEC keeps target unchanged Nov 27 2014
Europe gives green light to AbbVie hepatitis C drugs, others Nov 21 2014
Sanofi's dual-action biotech asthma drug performs well in test Nov 11 2014
Sanofi's dual-action biotech asthma drug performs well in test Nov 11 2014
City Diary: Mystery over Viking River Cruises' Chinese tipping charges Nov 07 2014
Artificial hips business boosts Smith & Nephew profit Oct 30 2014
European stocks close level before Fed outcome Oct 29 2014
Sanofi sacks CEO over management row, shares plunge Oct 29 2014
European stocks rise before Fed outcome Oct 29 2014
GLOBAL MARKETS-Stocks up, investors hope for comforting Fed message Oct 29 2014
Boardroom coup at Sanofi: directors oust chief executive Oct 29 2014
Europe open: Stocks rally ahead of US policy decision Oct 29 2014
European shares inch higher; Sanofi drops again Oct 29 2014
GLOBAL MARKETS-Shares rise as investors put faith in Fed's message Oct 29 2014
Sanofi shares slide after boss sacked Oct 29 2014
European shares rise ahead of Fed; Sanofi drops again Oct 29 2014
Sanofi's chief executive Viehbacher uncertain over future at drugmaker Oct 28 2014
Document for Sanofi Sep 25 2014
[video] Think Pfizer will come back to AstraZenaca: Pro May 02 2014
Glancy Binkow & Goldberg Reminds Investors of the Lead Plaintiff Deadline in the Class Action... Feb 04 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from... Jan 31 2014
An Option On Adoption Of A New Multiple Sclerosis Treatment Jan 29 2014
SANOFI CONTINGENT VALUE RIGHTS SHAREHOLDERS: The Alexander Firm P.C. Announces Upcoming Lead... Jan 28 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Sanofi Pharmaceuticals, Inc.... Jan 24 2014
[video] Bristol-Myers Squibb performance was staggering: Analyst Jan 23 2014
GCVRZ: Betting On The Sales Of Lemtrada In A Moving MS Drug Market Jan 19 2014
Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit on Behalf of Investors of Sanofi... Jan 17 2014
Lieff Cabraser Reminds Sanofi Investors of Upcoming Deadline in Class Action Litigation – GCVRZ Jan 17 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from... Jan 06 2014
Lieff Cabraser Announces Class Action Litigation Against Sanofi, Inc. - GCVRZ Dec 20 2013
SHAREHOLDER ALERT: Investors in Sanofi Contingent Value Rights Are Encouraged To Contact Wolf... Dec 19 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK